KURA
Kura Oncology, Inc.
NASDAQ · USHealthcareBiotechnology
$10.68-1.66%
Price as of Jul 20, 2026
KURA growth
Kura Oncology, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +5.4%
- EBITDA
- -64.2%
- EBIT
- -56.2%
- EPS
- -59.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- -4.4%
- EBITDA
- +114.1%
- EPS
- +50.5%
Three-year CAGR
- Revenue
- +25.2%
- EBITDA
- -62.7%
- EBIT
- -57.2%
- Net income
- -60.2%
- EPS
- -57.4%
- Free cash flow
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.